GANX · Gain Therapeutics, Inc.
$1.91
-0.09 (-4.50%)
At close · Aug 25
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report.”View the 10-Q filed Aug 11, 2026
Market Cap
$87.51M
Shares
43.64M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$55.18K
-60.6%
FY2023
Net Income
-$20.16M
+1.2%
FY2025
Operating Margin
-40328.26%
-27640.2pp
FY2023
Diluted EPS
-$0.61
+31.5%
FY2025
Operating Cash Flow
-$18.47M
+2.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | — | — | $55.18K | $140.11K | $164.99K | $28.88K | |
| $411.51K | — | — | $494.23K | $375.36K | $12.5K | $3637 | |
| $10.1M | $10.21M | $10.79M | $11.52M | $8.38M | $7.16M | $2.26M | |
| $9.19M | $8.5M | $9.56M | $10.79M | $9.54M | $6.83M | $1.25M | |
| — | $94.05K | $84.07K | $83.58K | $64.17K | $15.48K | $9592 | |
| $19.29M | $18.71M | $20.35M | $22.31M | $17.92M | $13.99M | $3.51M | |
| -$19.29M | -$18.71M | -$20.35M | -$22.25M | -$17.78M | -$13.83M | -$3.48M | |
| — | — | — | -40328.26% | -12688.1% | -8379.8% | -12047.54% | |
| — | -$18.62M | -$20.27M | -$22.17M | -$17.71M | -$13.81M | -$3.47M | |
| -$19.2M | -$19.3M | -$19.87M | -$22.19M | -$17.5M | -$13.89M | -$3.57M | |
| $906.54K | $861.12K | $536.82K | $79.28K | $92.98K | $4008 | $5386 | |
| -$20.11M | -$20.16M | -$20.41M | -$22.27M | -$17.59M | -$13.89M | -$3.58M | |
| — | — | — | -40354.33% | -12555.13% | -8418.86% | -12387.67% | |
| -$19.69M | -$19.14M | -$20.91M | -$22.06M | -$17.46M | -$13.83M | -$3.65M | |
| USD/shares | — | -$0.61 | -$0.89 | -$1.71 | -$1.48 | -$1.37 | -$1.33 |
| USD/shares | — | -$0.61 | -$0.89 | -$1.71 | -$1.48 | -$1.37 | -$1.33 |
| shares | — | 32.97M | 22.88M | 13.01M | 11.88M | 10.17M | 2.68M |
| shares | — | 32.97M | 22.88M | 13.01M | 11.88M | 10.17M | 2.68M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.06×
EV/EBIT
—
Peer median 10.95×
P/E (TTM)
—
Peer median 9.36×
Peer medians compare against the 301 similar-size Biotechnology companies (of 533 listed).
Valuation over time computed as of each quarter's filing date
Key facts
CIK
1819411
CUSIP
36269B105
13F (30d)
45 filings
45 filers
Visit website
Investor relations